Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 2;16(10):2349-2356.
doi: 10.1080/21645515.2020.1753440. Epub 2020 May 13.

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab

Erminia Ridolo  1 , Francesco Pucciarini  1 , Maria Cristina Nizi  1 , Eleni Makri  2 , Paola Kihlgren  1 , Lorenzo Panella  3 , Cristoforo Incorvaia  2
Affiliations

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab

Erminia Ridolo et al. Hum Vaccin Immunother. .

Abstract

The introduction of biologics for the treatment of patients with refractory asthma represented a marked therapeutic advance. For more than 10 y, the only biologic available has been the monoclonal anti-IgE antibody omalizumab, reserved for patients with asthma caused by perennial allergen. In recent years, other biologics have been licensed for the treatment of severe eosinophilic asthma. They include monoclonal antibodies that target the Th2-pathway cytokines, such as IL-5 (mepolizumab and reslizumab) or its receptor (benralizumab) and the IL-4 and IL-13 receptor (dupilumab). The effectiveness of these biologics was demonstrated in several placebo controlled trials, the main outcomes being the significant reduction of the rate of asthma exacerbation and the improvement of respiratory function in actively treated patients. Based on the further understanding of the pathogenesis of asthma, new cytokines network and new targets are emerging, such as thymic stromal lymphopoietin, which can activate Th2 cells, innate lymphoid cells, or both, or prostaglandin D2 (PGD2), to develop additional biologics.

Keywords: Severe asthma; benralizumab; biologics; dupilumab; mepolizumab; omalaizumab; reslizumab.

PubMed Disclaimer

References

    1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2163–69. doi:10.1016/S0140-6736(12)61729-2. - DOI - PMC - PubMed
    1. Leynaert B, Sunyer J, Garcia-Esteban R, Svanes C, Jarvis D, Cerveri I, Dratva J, Gislason T, Heinrich J, Janson C, et al. Gender differences in prevalence, diagnosis and incidence of allergic and non-allergic asthma: a population-based cohort. Thorax. 2012;67:625–31. doi:10.1136/thoraxjnl-2011-201249. - DOI - PubMed
    1. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, von Mutius E, Farrall M, Lathrop M, Cookson WOCM, et al. GABRIEL Consortium. A large-scale, consortium-based genome-wide association study of asthma. N Engl J Med. 2010;363:1211–21. doi:10.1056/NEJMoa0906312. - DOI - PMC - PubMed
    1. Portelli MA, Hodge E, Sayers I.. Genetic risk factors for the development of allergic disease identified by genome-wide association. Clin Exp Allergy. 2015;45:21–23. doi:10.1111/cea.12327. - DOI - PMC - PubMed
    1. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T-helper type 2-driven inflammation defines major sub-phenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–95. doi:10.1164/rccm.200903-0392OC. - DOI - PMC - PubMed